Insights from 2023 WCLC
WCLC 2023 Insights: "Phase 3 AEGEAN Study - Neoadjuvant Durvalumab + Chemo Followed by Adjuvant Durvalumab in Resectable EGFRm NSCLC"
By
Insights from 2023 WCLC
FEATURING
David Harpole
By
Insights from 2023 WCLC
FEATURING
David Harpole
Comments 0
Login to view comments.
Click here to Login
